Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Glaxo Says $13-a-Share Human Genome Offer Is ‘Full and Fair’

Don't Miss Out —
Follow us on:

April 19 (Bloomberg) -- GlaxoSmithKline Plc said its offer for Human Genome Sciences Inc. represents “full and fair value” and would deliver an “immediate and certain” benefit beyond what Human Genome can create as a stand-alone company.

“We are disappointed that Human Genome Sciences has rejected our offer without discussion and are confident that our offer is in the best interest of shareholders of both companies,” Glaxo Chief Executive Officer Andrew Witty said today in a statement.

“Now is the appropriate time in the evolution of our relationship for our two companies to combine,” Witty said. “GSK is uniquely positioned to realize the full value of Benlysta, albiglutide, darapladib and Human Genome Sciences’s other assets for the benefit of physicians, patients and shareholders.”

Link to Statement:{NSN M2Q5V33HBS3K <GO>}

Link to Company News:{GSK LN <Equity> CN <GO>} Link to Company News:{HGSI US <Equity> CN <GO>}

To contact the reporter on this story: Trista Kelley in London at

To contact the editor responsible for this story: Kristen Hallam at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.